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Abstract In a previous 15-day, Phase II study of patients
with de novo or persistent/recurrent Cushing’s disease (core
study), treatment with pasireotide 600 lg sc bid reduced
urinary free cortisol (UFC) levels in 76 % of patients and
normalized UFC in 17 %. The objective of this study was to
evaluate the efficacy and safety of extended treatment with
pasireotide. This was a planned, open-ended, single-arm,
multicenter extension study (primary endpoint: 6 months).
Patients aged C18 years with Cushing’s disease who com-
pleted the core study could enter the extension if they
achieved UFC normalization at core study end and/or
obtained significant clinical benefit. Of the 38 patients who
completed the core study, 19 entered the extension and 18
were included in the efficacy analyses (three responders, 11
reducers, four non-reducers in the core study). At data cut-
off, median treatment duration in the extension was
9.7 months (range: 2 months to 4.8 years). At extension
month 6, 56 % of the 18 patients had lower UFC than at core
baseline and 22 % had normalized UFC. Of the four patients
who remained on study drug at month 24, one had normal-
ized UFC. Reductions in serum cortisol, plasma adrenocor-
ticotropic hormone, body weight and diastolic blood
pressure were observed. The most common adverse events
were mild-to-moderate gastrointestinal disorders and
hyperglycemia. Pasireotide offers a tumor-directed medical
therapy that may be effective for the extended treatment of
some patients with Cushing’s disease.
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Cushing’s disease is the clinical consequence of chronic
hypercortisolism caused by an adrenocorticotropic hor-
mone (ACTH)-secreting pituitary adenoma [1]. Patients
with Cushing’s disease have 4.8-fold higher mortality than
the general population [2] and a high level of cardiovas-
cular, metabolic and osteoporotic comorbidities [2–4].
First-line treatment for patients with Cushing’s disease is
transsphenoidal surgery, with remission rates of 65–90 %
in patients with a microadenoma, if performed by an expert
pituitary surgeon [1]. Second-line options include repeat
surgery, radiotherapy, medical therapy and bilateral adre-
nalectomy [1]. However, lower success rates are seen after
repeat surgery than after the initial surgery, and hypopi-
tuitarism is more common [1]. Hypopituitarism is also
common after radiotherapy [5], whereas bilateral adrenal-
ectomy results in permanent hypoadrenalism [1].
The most commonly used medical therapies are ste-
roidogenesis inhibitors, none of which have been evalu-
ated in large, prospective clinical trials. These agents are
generally used off-label [1, 6]. Recently, pasireotide has
been approved as a medical therapy for Cushing’s disease
in the EU and US [7], and mifepristone is available to
treat hyperglycemia associated with hypercortisolism in
the US [8].
Corticotroph adenomas express multiple somatostatin
receptor subtypes (sst), making somatostatin analogues a
rational therapeutic option for patients with these tumors.
Pasireotide is a multireceptor-targeted somatostatin ana-
logue with high affinity for sst1, sst2 and sst3, and highest
affinity for sst5 [9]. The receptor sst5 is present on most
corticotroph adenomas [10]. In a 15-day, proof-of-concept,
Phase II study in patients with de novo or persistent/
recurrent Cushing’s disease, treatment with pasireotide
600 lg sc bid reduced urinary free cortisol (UFC) levels in
76 % (22/29) of patients and led to normal UFC levels in
five patients (17 %) [11]. This paper presents results from
the extension phase of the Phase II study and evaluates the
long-term efficacy and safety of pasireotide in patients who
chose to continue the medication.
Patients and methods
Patients
Patients with Cushing’s disease (aged C18 years) who had
completed the 15-day, proof-of-concept, Phase II core
study [11] were eligible to enter this extension phase if they
had normal 24-h UFC levels at the end of the core study
and/or, in the opinion of the investigator, obtained signif-
icant clinical benefit with pasireotide. Confirmation of
Cushing’s disease was previously described in the core
study [11]. Inclusion and exclusion criteria for the exten-
sion study are reported in the Supplementary Material.
This study was approved by the Independent Ethics
Committee, Institutional Review Board or Research Ethics
Board for each study center. The study was conducted
according to the ethical principles of the Declaration of
Helsinki. All patients provided written informed consent.
Study design
This open-ended, single-arm extension study (ClinicalTri-
als.gov NCT00171951) was a planned extension to the
15-day core study [11]. Patients who achieved normalized
UFC levels at the end of the core study continued at a dose
of 600 lg sc bid. If UFC levels increased, the pasireotide
dose could be increased to 900 lg sc bid. The dose of
pasireotide could be reduced by 150 lg per injection at any
time if the investigator believed that a drug-related adverse
event (AE) was present.
Patients were to be discontinued from the extension
study if they failed to demonstrate ongoing treatment
benefit, experienced an unacceptable AE (defined as drug-
related toxicity of Common Terminology Criteria [CTCAE
v3.0] [12] grade 3 or 4 that did not resolve to grade 1
within 24 h), experienced evidence of disease progression
or received any other therapeutic intervention for Cush-
ing’s disease (see Supplementary Material for further
details).
Endpoints
The primary efficacy outcome was the proportion of
patients with normalized UFC levels after 6 months of
treatment (normal UFC range: 55–276 nmol/24 h;
20–100 lg/24 h). Secondary objectives included assess-
ment of the safety and tolerability of multiple doses of
pasireotide and trough plasma concentrations of pasireo-
tide after chronic dosing.
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Assessments
Patients were classified as ‘UFC responders’ if their mean
UFC level at month 6 was in the normal range; as ‘UFC
reducers’ if their mean UFC level at month 6 was lower
than that at core study baseline but not within normal
limits; and as ‘UFC non-reducers’ if their mean UFC level
at month 6 was equal to or higher than that at core study
baseline or if the mean UFC level at month 6 was missing.
Patients who discontinued prior to month 6 were classified
as non-responders.
Blood samples for serum cortisol, plasma ACTH and
pharmacokinetic assessments were collected before the
morning pasireotide dose on study visit days. UFC assays
were conducted in two central laboratories, one in Europe
and the other in the US. Serum cortisol and plasma ACTH
assays were assessed centrally by one laboratory (see
Supplementary Material for further details).
Safety was assessed by recording all AEs, as well as by
regular monitoring of vital signs, physical condition, body
weight, hematology and blood chemistry. HbA1c levels
were recorded at extension baseline and then every
16 weeks. HbA1c categories were: \upper limit of normal
(ULN; normal defined as \5.7 %), between the ULN and
7 %, between 7 and 9 %, and over 9 %.
Statistical methods
Summary statistics were provided for the primary and
secondary endpoints. No formal statistical comparisons
were performed for this study because of the small sample
size. The analysis populations were defined as follows: the
intention-to-treat (ITT) and safety populations consisted of
patients who received at least one pasireotide dose in the
extension period. The primary efficacy population con-
sisted of those ITT patients whose mean UFC at core
baseline, based on at least two UFC samples, was [ULN.
Results
Of 38 patients who completed 15 days’ pasireotide ther-
apy, 19 entered this extension phase, 17 women and two
men, all Caucasian, mean age 43 years (range 22–73,
standard deviation [SD]: 11.6). One patient had normal
UFC levels on entry into the core study and was therefore
excluded from the primary efficacy analysis. Three patients
who entered the extension study had normal UFC levels at
the end of the core study. Between completing the core
study and entering the extension, 10 patients experienced a
treatment interval. During this interim period, patients did
not receive pasireotide (range of interval: 6–367 days).
Information on other treatments for Cushing’s disease was
not collected during the treatment intervals (see Supple-
mentary Material for further details).
All patients entered the extension phase on a dose of
600 lg sc bid. At data cut-off, the treatment duration
ranged from 2 months to 4.8 years and the median treat-
ment duration was 9.7 months at that time. Three patients
were continuing to receive treatment at the time of the data
cut-off. Overall, 16 patients discontinued treatment during
the extension study. The main reasons for discontinuation
were to start new therapy for Cushing’s disease (five
[26.3 %]), withdrawal of consent (three [15.8 %]), unsat-
isfactory therapeutic effect after 5–10 months (three
[15.8 %]), AE (one [5.3 %]: new-onset type 2 diabetes
mellitus), and abnormal laboratory value (two [10.5 %]:
one increased HbA1c and glucose and one elevated UFC).
Seven patients discontinued treatment prior to month 6.
Effects of pasireotide therapy at month 6
UFC levels at month 6
Of the 18 patients included in the primary efficacy analysis,
four had normal UFC levels at month 6 (responders, 22.2 %;
95 % confidence interval [CI] 6.4–47.6). Six patients (33.3 %)
achieved a reduction in mean UFC, but not to within normal
range (reducers). One patient had a mean UFC level greater
than at baseline and was classified as a non-reducer; the
remaining seven patients were also considered to be non-
reducers because they discontinued treatment prior to month 6.
In the 18 patients included in the primary efficacy
analyses, mean UFC (± SD) decreased from core baseline
by -802 ± 819 nmol/24 h to month 6 of the extension
(Table 1).
Serum cortisol and plasma ACTH levels at month 6
Consistent with the reduction in UFC levels, mean serum
cortisol (±SD) and plasma ACTH levels decreased from core
baseline by -151 ± 309 nmol/L and -3.4 ± 9.4 pmol/L,
respectively, at month 6 (Table 1).
Ongoing effects of pasireotide therapy up to 24 months
The reductions in mean UFC persisted in the four patients
who were on study drug at month 24 (Table 1). Of these
four patients, three had [50 % reduction in mean UFC
from core baseline. One patient had been a responder at the
end of the core study. Despite variability in serum cortisol
levels, there was an overall reduction in serum cortisol and
plasma ACTH relative to core baseline that was maintained
throughout the extension (Table 1). There was an overall
reduction in body weight and diastolic blood pressure over
time (Table 2). Clinical improvements were not limited to
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patients who achieved UFC control. The sample size was
not large enough to assess the significance of these results.
Pharmacokinetics
Mean ± SD Ctrough levels at month 6 were 17.4 ± 11.6
and 19.1 ± 10.9 lg/L in UFC responders (n = 4) and
reducers (n = 6), respectively, and 5.2 lg/L in non-
reducers (n = 1). These values were higher than those at
the end of the core study, when mean ± SD Ctrough levels
were 7.0 ± 4.3 and 4.4 ± 1.1 lg/L in UFC responders and
reducers, respectively, and 2.7 lg/L in non-reducers.
Safety and tolerability of pasireotide up to month 24
All patients experienced at least one AE during the study. With
the exception of hyperglycemia, AEs were generally as
expected and were mostly related to transient gastrointestinal
Table 1 Change in UFC, serum cortisol and plasma ACTH from core baseline to day 15 and months 6, 12 and 24
Core baseline Day 15 Month 6 Month 12 Month 24
UFC (nmol/24 h)
[lg/24 h]
na 17 17 11 4 4
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Core baseline is considered as pre-dose on day 1. Normal range for UFC: 55–276 nmol/24 h (20–100 lg/24 h); normal range for serum cortisol:
221–690 nmol/L (8.0–25.0 lg/dL; 09:00 h measure); normal range for plasma ACTH: \10 pmol/L (\45.5 pg/mL). The mean change from
baseline was calculated only in those patients with evaluable measurements at baseline and month 6
a n is the number of patients in the primary efficacy population who have a mean UFC value at core baseline and at a particular visit
b n = 16
c n = 10
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discomfort (Table 3). One patient discontinued treatment
because of an AE (new-onset type 2 diabetes mellitus). Thir-
teen patients reported a hyperglycemia-related adverse event:
11 patients had a reported AE of hyperglycemia, one patient
had increased blood glucose, and one patient reported type 2
diabetes. Two patients had grade 4 AEs: one was increased c-
glutamyltransferase levels and the other was type 2 diabetes
mellitus. Both events were suspected by the investigator to be
related to study drug. No patients died during the study.
At extension baseline, eight of the 19 patients had
HbA1c values available, all of which were \ULN (exten-
sion baseline mean ± SD: 5.78 ± 0.51 %). HbA1c was not
measured during the core study. Six patients had post-
baseline HbA1c levels shifted to a higher category at some
point during the extension and were treated with
modification of diet or with antidiabetic medication,
including metformin, glimepiride, exenatide, pioglitazone
or insulin. Five of these six patients remained at a higher
post-baseline HbA1c level at their last assessment.
All patients experienced an increase in fasting plasma
glucose (FPG) level at some point during the extension
study (see Supplementary Material). Of the 16 patients
with normal FPG at extension baseline, FPG levels shifted
to between 100 and \126 mg/dL (5.6 to \7.0 mmol/L) in
six patients, between 126 and \200 mg/dL (7.0 to
\11.1 mmol/L) in four patients and C200 mg/dL
(C11.1 mmol/L) in six patients at some point during the
extension study. All patients had improved FPG levels at
their last assessment.
Electrocardiogram intervals were generally within nor-
mal ranges during the study. One patient had a newly
occurring QT of 450–480 ms, another patient had a newly
occurring QTcB of 450–480 ms, and one patient had a
QRS interval of [110 ms (not clinically significant).
Discussion
The results of this study support the extended treatment
with pasireotide in some patients with Cushing’s disease.
After 6 months of therapy, 10 of 18 patients (56 %)
achieved reduced UFC levels compared with core baseline,
and four patients (22 %) had normalized UFC levels. Mean
serum cortisol and plasma ACTH levels also decreased
over this period, irrespective of whether UFC control was
Table 2 Change in vital signs from core baseline to day 15 and months 6, 12 and 24
Core baseline Day 15 Month 6 Month 12 Month 24
Body weight (kg)
n 19 19 12 7 4


















Systolic blood pressure (mmHg)
n 19 19 12 7 4


















Diastolic blood pressure (mmHg)
n 19 19 12 7 4


















Table 3 Most frequently occurring adverse events ([5 patients)
regardless of study-drug relationship




Abdominal pain 9 (47.4)
Headache 7 (36.8)
Injection-site pain 6 (31.6)
Dizziness 5 (26.3)
Fatigue 5 (26.3)
Injection-site pruritus 5 (26.3)
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achieved. These pasireotide-induced reductions were
maintained in four patients who were treated for over
24 months. These findings led to the initiation of a Phase
III study of pasireotide in 162 patients with persistent/
recurrent or de novo Cushing’s disease [13]. The Phase III
study found that pasireotide treatment led to a rapid and
sustained decrease in UFC levels. The UFC normalization
rate at month 6 in the current study (22 %) and the Phase
III study (20.4 %) was similar. Based on the findings from
the Phase III study, pasireotide was approved in the EU and
US for the treatment of patients with Cushing’s disease for
whom surgery is not an option or who decline surgery. The
current study shows that this response can be maintained
for at least 24 months in some patients. In fact, a patient
case from this study has illustrated long-term UFC control
without escape or serious AEs during[7 years of treatment
with pasireotide sc [14].
Long-term reductions in body weight and diastolic
blood pressure were found in the current study, which in
part may reflect the sustained reduction in cortisol levels
and may attenuate the considerable morbidity observed in
patients with Cushing’s disease [2–4]. While the sample
size in the present study was not large enough to test the
statistical significance of this result, significant improve-
ments in clinical signs and symptoms were observed in the
much larger Phase III study of pasireotide in Cushing’s
disease [13, 15].
The results of the current study suggest that there may
be a relationship between the plasma concentration of pa-
sireotide and its effect on UFC levels. Interestingly, trough
plasma concentrations of pasireotide were higher at month
6 than at the end of the core study. The reasons for this are
unclear, and it is difficult to fully interpret this finding
because of the small sample size.
The safety profile of pasireotide in this study is similar
to that of previous pasireotide studies [11, 13]. In line with
the safety profile of other somatostatin analogues, the most
frequently occurring drug-related AEs are mild-to-moder-
ate and transient gastrointestinal disturbances. The preva-
lence of hyperglycemia-related AEs in this study was
higher than seen with other somatostatin analogues in other
indications [16–18]. Patients with Cushing’s disease are
predisposed to alterations in glucose homeostasis [19], and
a higher prevalence of diabetes mellitus and glucose
intolerance has been reported in patients with Cushing’s
disease compared with the general population [20]. In the
present study, none of the eight patients with available
glycemic data had elevated HbA1c levels at extension
baseline. However, the possibility of glucose intolerance
could not be excluded in these patients. During the treat-
ment period, hyperglycemia-related AEs were reported in
68 % of patients (13/19). Seven continued pasireotide
treatment with concomitant treatment for hyperglycemia-
related AEs, five continued with no medication for
hyperglycemia and one patient discontinued. It is therefore
important to monitor glucose levels during pasireotide
treatment and initiate prompt medical intervention and
close follow-up [21].
There are several limitations of this study that may have
affected the findings, most notably the small number of
patients who entered the extension period and who continued
to receive pasireotide after 6 months. This limits the con-
clusions that can be drawn from some of the analyses, par-
ticularly of the pharmacokinetic data. In addition, HbA1c
measurements were available for only 42 % of patients at
baseline, which rendered the study less informative than
planned with regard to the effects of pasireotide on glucose
homeostasis. However, the results of the study are consistent
with the much larger Phase III study of pasireotide [13].
In conclusion, pasireotide offers a tumor-directed med-
ical therapy and may be effective for the long-term treat-
ment of some patients with Cushing’s disease.
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